At the news
? BEARISHIMPACT 6/10 EFFECT filed Apr 6, 2026 at 00:15 ET
Oncolytics Biotech's S-3 shelf registration has become effective, allowing the company to issue up to $250 million in securities, including common stock, preferred stock, warrants, and other instruments. This follows a recent shelf filing and enables the company to raise capital opportunistically, creating a potential overhang of future dilution. The effectiveness date was April 3, 2026.
- S-3 shelf registration became effective on April 3, 2026
- Company may offer up to $250 million in securities, including common stock, preferred stock, warrants, purchase contracts, and units
- Shelf registration allows for opportunistic capital raises over time
- Prior shelf registration had $139 million in unsold capacity carried forward
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access